Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out of four ...
Axsome Therapeutics said on Monday it would seek marketing approval next year for its oral drug to treat agitation in patients with Alzheimer's disease, after it succeeded in three out of four ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback